Using cancer types subgroup analyses, we observed that CTLA-4 319C/T polymorphism was significantly associated with the CLL risk in the recessive model (TT vs. TC+CC: OR: 0.28, 95%CI:0.08-0.98, P = 0.047), dominant model (CC vs. TC+TT: OR: 1.64, 95%CI:1.07-2.51, P = 0.024), homozygous model (TT vs. CC: OR: 0.26, 95%CI:0.07-0.90, P = 0.034), and allelic model (T vs C: OR: 0.60, 95%CI:0.42-0.87, P = 0.007). This evidence concerns the gene CTLA4 and cancer.